Goldman Sachs analyst, Terence Flynn, reiterated his Buy rating on shares of Amgen (NASDAQ: AMGN) after the FDA advisory committee ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE